Compare QIPT & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | QIPT | NYXH |
|---|---|---|
| Founded | 1993 | 2009 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 161.9M | 190.6M |
| IPO Year | 2012 | 2021 |
| Metric | QIPT | NYXH |
|---|---|---|
| Price | $3.65 | $3.17 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $3.83 | ★ $11.67 |
| AVG Volume (30 Days) | ★ 378.6K | 56.7K |
| Earning Date | 03-27-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $245,359,000.00 | N/A |
| Revenue This Year | $28.30 | $97.32 |
| Revenue Next Year | $1.79 | $241.74 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.37 | $3.37 |
| 52 Week High | $3.65 | $11.87 |
| Indicator | QIPT | NYXH |
|---|---|---|
| Relative Strength Index (RSI) | 65.72 | 28.09 |
| Support Level | $3.55 | N/A |
| Resistance Level | N/A | $5.02 |
| Average True Range (ATR) | 0.01 | 0.27 |
| MACD | -0.00 | -0.08 |
| Stochastic Oscillator | 80.00 | 1.47 |
Quipt Home Medical Corp is a provider of durable medical equipment (DME) and home medical equipment (HME) in the United States. The Company specializes in delivering in-home treatments for the management of chronic conditions, with a primary focus on respiratory diseases, and supports patients with heart and pulmonary diseases, sleep apnea, reduced mobility, and other chronic health challenges. Its products and services include Sleep Apnea and PAP treatment, home medical equipment, home ventilation, and custom mobility solutions. The Company operates in a single business segment, comprising the sale and rental of medical equipment and related devices, and serves patients across 27 states in the United States.
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.